Q4 2019 Biogaia AB Earnings Call Transcript
Ladies and gentlemen, welcome to BioGaia Q4 report 2019. Today, I'm pleased to present Isabelle Ducellier, CEO. (Operator Instructions)
Isabelle, please begin.
()-&
Yes. Good morning, and thank you who follow BioGaia. So I'm going to present the last quarter of 2019, starting by saying that in terms of sales of our products, we had a good quarter with an increase of 6% of our product sales. Having said that, as everybody is well informed about, due to the loss of the GUM contract, royalty contract with Nestlé and the delays and problem with delivery with (inaudible) in Q4, the total sales have decreased by minus 1%.
If we look at the product sales more specifically, we are very happy about the last quarter for our Pediatrics portfolio that presented a very nice increase of 10%. In terms of specific SKUs, the Protectis drops against colic for kids has been showing a very good growth. And 2019 has been a very good year for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |